Just – Evotec Biologics Secures Grant for AI in Monoclonal Antibody Development

Just – Evotec Biologics, a subsidiary of Evotec SE, announced receiving a grant from the Gates Foundation. This funding aims to optimize monoclonal antibodies (mAbs) and other biologic modalities for wider access. Over the next three years, the investment will support ten new projects for molecular optimization, enhancing factors like titer, pharmacokinetics, immunogenicity, and stability.

The Seattle-based company will leverage its J.MD™ Molecular Design service, part of their J.DESIGN™ platform. This incorporates advanced computational and high-throughput methodologies, ensuring manufacturability, stability, and efficacy from development's earliest stages. The intent is to make biologics more affordable, particularly for low- and middle-income countries.

Dr. Linda Zuckerman of Just – Evotec Biologics emphasized their commitment to reducing development costs and expanding global access. The grant continues their collaboration with the Gates Foundation, started in 2014, facilitating biotherapeutic development targeting global health concerns.